Abstract 1238
Background
Bone and kidneys are among the main affected organ systems in symptomatic multiple myeloma (MM) and may be associated with debilitating complications. Thus, bone health and renal protection are at the core of MM management. Bisphosphonates (BP) are recommended for prevention of bone complications in all newly diagnosed symptomatic MM patients, but BPs are also potentially nephrotoxic and are cleared by the kidneys. This study describes the routine clinical use of BP among MM patients in Denmark.
Methods
Adult patients newly diagnosed with MM between 01.01.2005 and 30.06.2015 were identified in the Danish National Multiple Myeloma Registry, and information on BP treatment in first-line (1L) anti-MM therapy was analyzed.
Results
Among 2,633 MM patients with information on BP treatment in 1L, 1,838 (69.8%) received BP. Median time from MM diagnosis to BP treatment was 19 days (IQR: 9, 35). Receipt of BP among 1L-treated patients by therapy was: 79.4% (635/799) in autologous stem cell transplant recipients, 75.0% (793/1,058) in patients treated with conventional chemotherapy, and 70.2% (903/1,286) in those treated with bortezomib-, lenalidomide-, or thalidomide-containing regimens. Among the BP-treated patients, 67.2% (543/1,838) had no recorded hypercalcemia at MM diagnosis, 81.0% (1,489/1,838) had a record of skeletal-related events (SRE) in the 12 months before MM diagnosis, and 80.0% (1,470/1,838) had a record of osteolytic foci at 1L. An additional 431 patients had a record of osteolytic foci but no record of BP treatment. Patients without a record of BP treatment had higher prevalence of overall hospital-registered comorbidity, anemia, or higher ISS stage at MM diagnosis than patients with a record of BP treatment. Severe renal impairment (stages 4 - 5) was recorded at MM diagnosis in 31.8% of patients with no BP record and in 12.6% of patients with BP record at 1L start.
Conclusions
In newly diagnosed MM patients receiving 1L, co-administration of BP and anti-MM therapy is widespread, though less prevalent in patients with renal impairment or comorbidity burden.
Clinical trial identification
Legal entity responsible for the study
Aarhus University.
Funding
This study was funded by Amgen Inc. via institutional research grant to and administered by Aarhus University.
Editorial Acknowledgement
Disclosure
V. Ehrenstein, A.G. Ording, S.P. Ulrichsen: Employee of Aarhus University. I.T. Andersen, C. Helleberg, T. Silkjær, N. Abildgaard: Employee of the listed institution. A. Seesaghur, R. Hernandez, D. Niepel: Employee and stockholder: Amgen.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract